KR20250066486A - 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 - Google Patents

혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 Download PDF

Info

Publication number
KR20250066486A
KR20250066486A KR1020257014548A KR20257014548A KR20250066486A KR 20250066486 A KR20250066486 A KR 20250066486A KR 1020257014548 A KR1020257014548 A KR 1020257014548A KR 20257014548 A KR20257014548 A KR 20257014548A KR 20250066486 A KR20250066486 A KR 20250066486A
Authority
KR
South Korea
Prior art keywords
pkal
plasma
subject
inhibitor
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257014548A
Other languages
English (en)
Korean (ko)
Inventor
다니엘 제이. 섹스톤
라이언 파우셋
존 에이. 케니스톤
그레고리 피. 콘리
앤드류 닉슨
크리스토퍼 텐후어
버트 아델만
Original Assignee
다케다 파머수티컬 컴패니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52993413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20250066486(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다케다 파머수티컬 컴패니 리미티드 filed Critical 다케다 파머수티컬 컴패니 리미티드
Publication of KR20250066486A publication Critical patent/KR20250066486A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4713—Plasma globulins, lactoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96458—Factor XII (3.4.21.38)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
KR1020257014548A 2013-10-21 2014-10-17 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 Pending KR20250066486A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361893505P 2013-10-21 2013-10-21
US61/893,505 2013-10-21
US201461939837P 2014-02-14 2014-02-14
US61/939,837 2014-02-14
PCT/US2014/061247 WO2015061183A1 (en) 2013-10-21 2014-10-17 Assays for determining plasma kallikrein system biomarkers
KR1020237012295A KR20230054745A (ko) 2013-10-21 2014-10-17 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012295A Division KR20230054745A (ko) 2013-10-21 2014-10-17 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법

Publications (1)

Publication Number Publication Date
KR20250066486A true KR20250066486A (ko) 2025-05-13

Family

ID=52993413

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020257014548A Pending KR20250066486A (ko) 2013-10-21 2014-10-17 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR1020227027698A Active KR102521947B1 (ko) 2013-10-21 2014-10-17 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR1020167013432A Active KR102432826B1 (ko) 2013-10-21 2014-10-17 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR1020237012295A Ceased KR20230054745A (ko) 2013-10-21 2014-10-17 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227027698A Active KR102521947B1 (ko) 2013-10-21 2014-10-17 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR1020167013432A Active KR102432826B1 (ko) 2013-10-21 2014-10-17 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR1020237012295A Ceased KR20230054745A (ko) 2013-10-21 2014-10-17 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법

Country Status (13)

Country Link
US (2) US11372002B2 (enExample)
EP (2) EP3060582B1 (enExample)
JP (4) JP6757252B2 (enExample)
KR (4) KR20250066486A (enExample)
CN (1) CN105873951A (enExample)
AU (3) AU2014340450B2 (enExample)
BR (1) BR112016008970B1 (enExample)
CA (1) CA2927824C (enExample)
DK (1) DK3060582T3 (enExample)
ES (1) ES2837858T3 (enExample)
IL (3) IL289514B2 (enExample)
PL (1) PL3060582T3 (enExample)
WO (1) WO2015061183A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
IL269565B2 (en) * 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
CN111044725B (zh) 2013-01-20 2024-03-29 武田药品工业株式会社 缓激肽介导的病症的评估和治疗
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
KR102424183B1 (ko) 2014-01-21 2022-07-26 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US20180298110A1 (en) * 2015-03-30 2018-10-18 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
US10870115B2 (en) * 2015-08-13 2020-12-22 Dyax Corp. Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
JP6903648B2 (ja) 2015-10-19 2021-07-14 ダイアックス コーポレーション 切断高分子量キニノーゲンを検出するイムノアッセイ
EP3390439B1 (en) 2015-12-15 2025-03-12 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
BR112019005172A2 (pt) * 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
EP3513196A1 (en) * 2016-09-16 2019-07-24 Dyax Corp. Protein biomarkers for diseases associated with the contact activation system
MX2019002918A (es) * 2016-09-16 2019-07-18 Dyax Corp Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
WO2019165308A1 (en) * 2018-02-22 2019-08-29 The Regents Of The University Of California Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema
CN111057745B (zh) * 2019-12-30 2022-08-12 中国科学院生态环境研究中心 一种物质的血液毒性效应的高通量筛选方法
CN113777331A (zh) * 2020-06-09 2021-12-10 张曼 尿液激肽原-1及其多肽片段在烧伤中的应用
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途
EP4548103A2 (en) * 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment
WO2025153806A1 (en) * 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) * 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
KR960009766B1 (ko) * 1986-09-10 1996-07-24 니혼 소오끼 세이야꾸 가부시기가이샤 생리 활성물질 측정법
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993003748A1 (en) 1991-08-13 1993-03-04 Temple University - Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) * 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
ATE528014T1 (de) 2002-06-07 2011-10-15 Dyax Corp Polypeptid mit modifizierten kunitz domains
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
LT1981519T (lt) 2005-12-29 2018-04-25 Dyax Corp. Proteazės slopinimas
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US7625944B2 (en) 2006-07-31 2009-12-01 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
JP2010510528A (ja) 2006-11-22 2010-04-02 ライフ テクノロジーズ コーポレーション 自己免疫疾患のバイオマーカー
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
EP2216651A4 (en) 2007-10-18 2010-12-01 Miyazaki Prefectural Ind Suppo BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE
WO2009053050A1 (en) 2007-10-22 2009-04-30 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
JP5348595B2 (ja) 2008-07-07 2013-11-20 日本臓器製薬株式会社 線維筋痛症の検査法
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
EP2369930A4 (en) 2008-12-02 2012-10-03 Joslin Diabetes Ct METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN102762203A (zh) 2009-12-18 2012-10-31 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂的前药
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
EP2593121A2 (en) 2010-07-13 2013-05-22 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
AU2011336345B2 (en) 2010-12-02 2016-07-07 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
AU2012267546B2 (en) * 2011-06-10 2015-12-24 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
FR2983215B1 (fr) * 2011-11-28 2013-12-20 Univ Grenoble 1 Dosage de la capacite de controle de c1inh
CN111044725B (zh) 2013-01-20 2024-03-29 武田药品工业株式会社 缓激肽介导的病症的评估和治疗
US20140220552A1 (en) 2013-02-01 2014-08-07 Becton, Dickinson And Company Blood collection devices containing contact pathway inhibition additives
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
KR102424183B1 (ko) 2014-01-21 2022-07-26 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
JP6903648B2 (ja) 2015-10-19 2021-07-14 ダイアックス コーポレーション 切断高分子量キニノーゲンを検出するイムノアッセイ
EP3390439B1 (en) 2015-12-15 2025-03-12 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
US20230072523A1 (en) 2020-01-28 2023-03-09 Orgenesis Inc. Process and system for acellular therapy

Also Published As

Publication number Publication date
WO2015061183A1 (en) 2015-04-30
BR112016008970A2 (pt) 2017-09-19
IL274055A (en) 2020-06-30
US12442824B2 (en) 2025-10-14
AU2014340450B2 (en) 2020-05-21
KR102521947B1 (ko) 2023-04-14
CN105873951A (zh) 2016-08-17
JP7135039B2 (ja) 2022-09-12
US20220291232A1 (en) 2022-09-15
CA2927824C (en) 2025-06-17
US20160252527A1 (en) 2016-09-01
JP2016536012A (ja) 2016-11-24
DK3060582T3 (da) 2020-12-21
AU2024203355A1 (en) 2024-06-06
AU2020217316B2 (en) 2024-02-22
IL289514B1 (en) 2023-09-01
EP3060582A4 (en) 2017-07-19
AU2014340450A1 (en) 2016-06-02
EP3060582B1 (en) 2020-09-23
IL274055B (en) 2022-02-01
AU2020217316A1 (en) 2020-08-27
BR112016008970B1 (pt) 2023-12-26
JP2022188017A (ja) 2022-12-20
EP3808857A1 (en) 2021-04-21
CA2927824A1 (en) 2015-04-30
IL289514A (en) 2022-03-01
KR20220119171A (ko) 2022-08-26
IL289514B2 (en) 2024-01-01
EP3060582A1 (en) 2016-08-31
IL245205A0 (en) 2016-06-30
KR20230054745A (ko) 2023-04-25
IL245205B (en) 2020-05-31
KR102432826B1 (ko) 2022-08-16
PL3060582T3 (pl) 2021-05-04
EP3808857B1 (en) 2025-12-10
KR20160093604A (ko) 2016-08-08
JP2021003114A (ja) 2021-01-14
US11372002B2 (en) 2022-06-28
JP7668772B2 (ja) 2025-04-25
JP2024150637A (ja) 2024-10-23
ES2837858T3 (es) 2021-07-01
JP6757252B2 (ja) 2020-09-16

Similar Documents

Publication Publication Date Title
US12442824B2 (en) Assays for determining plasma kallikrein system biomarkers
JP7516451B2 (ja) ｐＫａｌ関連疾病の評価、アッセイおよび治療
JP6772237B2 (ja) ブラジキニン媒介障害の評価および治療
HK40048781A (en) Assays for determining plasma kallikrein system biomarkers

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250430

Application number text: 1020237012295

Filing date: 20230411

PA0201 Request for examination
PG1501 Laying open of application